In HER2+ breast cancer, elevated TILs at diagnosis result in a greater response to adjuvant trastuzumab treatment [8], and TILs are predictors of complete pathologic response (pCR) after neoadjuvant treatment [9]. The gene discussed is ERBB2; the disease is breast carcinoma.